Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | ACLY | P53396 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1200189 | 0.87 | KCNH2 (0.65) | ALDH1A1HPGDHSD17B10MEN1KMT2A | |
| SCHEMBL2747643 | 0.87 | ACLY (0.53) | ALDH1A1HPGDHSD17B10ACLYMEN1 | |
| SCHEMBL2158425 | 0.84 | ACLY (0.54) | ALDH1A1HPGDHSD17B10ACLYMEN1 | |
| SCHEMBL1200176 | 0.81 | ACLY (0.64) | ALDH1A1HPGDACLYMEN1KMT2A | |
| SCHEMBL2748302 | 0.79 | ACLY (0.55) | ALDH1A1HPGDHSD17B10ACLYMEN1 | |
| SCHEMBL4569871 | 0.79 | ACLY (0.52) | HSD17B10ACLYMEN1KMT2AKCNH2 | |
| SCHEMBL2158731 | 0.79 | ALDH1A1 (0.57) | ALDH1A1HPGDHSD17B10MEN1KMT2A | |
| SCHEMBL2158447 | 0.77 | NPSR1 (0.61) | ALDH1A1HPGDHSD17B10MEN1KMT2A | |
| SCHEMBL12464633 | 0.77 | ALDH1A1 (0.55) | ALDH1A1HPGDHSD17B10MEN1KMT2A | |
| SCHEMBL2747872 | 0.76 | ACLY (0.52) | HPGDHSD17B10ACLYMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228471-A1 | MOF, MOF LINKERS AND MANUFACTURING METHOD THEREOF | UNIVERSITEIT ANTWERPEN (BE) | 2024-07-11 | — | — | US | disclosed |
| EP-4326436-A1 | MOF, MOF LINKERS AND MANUFACTURING METHOD THEREOF | Universiteit Antwerpen (BE) | 2024-02-28 | — | — | EP | disclosed |
| US-8329924-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20110200553-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200553-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, ZC3HAV1, MAVS | ALDH1A1 684/4885HPGD 2916/4885HSD17B10 1157/4885 |
| US-20240228471-A1 | MOF, MOF LINKERS AND MANUFACTURING METHOD THEREOF | ILK, MTCL3, FTO | ALDH1A1 979/4885HPGD 2459/4885HSD17B10 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.